# Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects

> **NCT00530452** · PHASE2 · UNKNOWN · sponsor: **CrystalGenomics, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Osteoarthritis, Knee
- Osteoarthritis, Hip

## Interventions

- **DRUG:** CG100649
- **DRUG:** Silicified microcrystalline cellulose + talc

## Key facts

- **NCT ID:** NCT00530452
- **Lead sponsor:** CrystalGenomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2008-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00530452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00530452, "Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00530452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*